NASDAQ:BPTH - Bio-Path Stock Price, News & Analysis

$12.19
+0.01 (+0.08 %)
(As of 08/19/2019 01:32 AM ET)
Today's Range
$12.09
Now: $12.19
$13.41
50-Day Range
$12.01
MA: $13.31
$15.15
52-Week Range
$1.61
Now: $12.19
$73.52
Volume156,800 shs
Average Volume80,881 shs
Market Capitalization$35.11 million
P/E RatioN/A
Dividend YieldN/A
Beta3.16
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BPTH
CUSIPN/A
Phone832-742-1357

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$40,000.00
Book Value$6.21 per share

Profitability

Net Income$-8,580,000.00

Miscellaneous

Employees8
Market Cap$35.11 million
Next Earnings Date11/21/2019 (Estimated)
OptionableNot Optionable

Receive BPTH News and Ratings via Email

Sign-up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter.


Bio-Path (NASDAQ:BPTH) Frequently Asked Questions

What is Bio-Path's stock symbol?

Bio-Path trades on the NASDAQ under the ticker symbol "BPTH."

When did Bio-Path's stock split? How did Bio-Path's stock split work?

Bio-Path's stock reverse split before market open on Friday, January 18th 2019. The 1-20 reverse split was announced on Friday, January 18th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 17th 2019. An investor that had 100 shares of Bio-Path stock prior to the reverse split would have 5 shares after the split.

How were Bio-Path's earnings last quarter?

Bio-Path Holdings Inc (NASDAQ:BPTH) issued its quarterly earnings results on Thursday, August, 15th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.60) by $0.27. View Bio-Path's Earnings History.

When is Bio-Path's next earnings date?

Bio-Path is scheduled to release their next quarterly earnings announcement on Thursday, November 21st 2019. View Earnings Estimates for Bio-Path.

What price target have analysts set for BPTH?

1 Wall Street analysts have issued 1-year target prices for Bio-Path's shares. Their forecasts range from $28.00 to $28.00. On average, they expect Bio-Path's stock price to reach $28.00 in the next twelve months. This suggests a possible upside of 129.7% from the stock's current price. View Analyst Price Targets for Bio-Path.

What is the consensus analysts' recommendation for Bio-Path?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Path in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bio-Path.

Has Bio-Path been receiving favorable news coverage?

Media coverage about BPTH stock has been trending negative this week, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Bio-Path earned a news sentiment score of -2.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Bio-Path.

Are investors shorting Bio-Path?

Bio-Path saw a increase in short interest during the month of July. As of July 31st, there was short interest totalling 247,000 shares, an increase of 5.2% from the June 30th total of 234,900 shares. Based on an average daily trading volume, of 193,000 shares, the short-interest ratio is currently 1.3 days. Currently, 14.4% of the company's stock are short sold. View Bio-Path's Current Options Chain.

Who are some of Bio-Path's key competitors?

What other stocks do shareholders of Bio-Path own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Path investors own include NVIDIA (NVDA), Canopy Growth (CGC), Palatin Technologies (PTN), Energy Transfer LP Unit (ET), Advanced Micro Devices (AMD), Micron Technology (MU), Trevena (TRVN), Viking Therapeutics (VKTX), Alibaba Group (BABA) and Amarin (AMRN).

Who are Bio-Path's key executives?

Bio-Path's management team includes the folowing people:
  • Mr. Peter H. Nielsen, Co-Founder, Chairman, CEO, Pres, CFO & Treasurer (Age 70)
  • Mr. Douglas P. Morris, Co-Founder, Director of Investor Relations, Sec. & Director (Age 63)
  • Mr. Anthony Price MBA, Director of Fin. and Accounting
  • Dr. Alan MacKenzie Ph.D., Consultant
  • Dr. Thomas A. Walker Ph.D., Consultant

Who are Bio-Path's major shareholders?

Bio-Path's stock is owned by a number of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (4.27%), BlackRock Inc. (1.66%), Vanguard Group Inc. (0.99%) and Morgan Stanley (0.70%). View Institutional Ownership Trends for Bio-Path.

Which institutional investors are selling Bio-Path stock?

BPTH stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for Bio-Path.

Which institutional investors are buying Bio-Path stock?

BPTH stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, BlackRock Inc. and Vanguard Group Inc.. View Insider Buying and Selling for Bio-Path.

How do I buy shares of Bio-Path?

Shares of BPTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bio-Path's stock price today?

One share of BPTH stock can currently be purchased for approximately $12.19.

How big of a company is Bio-Path?

Bio-Path has a market capitalization of $35.11 million and generates $40,000.00 in revenue each year. The company earns $-8,580,000.00 in net income (profit) each year or ($14.38) on an earnings per share basis. Bio-Path employs 8 workers across the globe.View Additional Information About Bio-Path.

What is Bio-Path's official website?

The official website for Bio-Path is http://www.biopathholdings.com/.

How can I contact Bio-Path?

Bio-Path's mailing address is 4710 BELLAIRE BOULEVARD SUITE 210, BELLAIRE TX, 77401. The company can be reached via phone at 832-742-1357 or via email at [email protected]


MarketBeat Community Rating for Bio-Path (NASDAQ BPTH)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  219 (Vote Outperform)
Underperform Votes:  197 (Vote Underperform)
Total Votes:  416
MarketBeat's community ratings are surveys of what our community members think about Bio-Path and other stocks. Vote "Outperform" if you believe BPTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel